Serina Therapeutics
32 hedge funds and large institutions have $4.09M invested in Serina Therapeutics in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 4 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.17% less ownership
Funds ownership: 12.78% → 12.61% (-0.17%)
9% less funds holding
Funds holding: 35 → 32 (-3)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
67% less capital inflows, than outflows
Capital inflows: $35.1K | Capital outflows: $108K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
+$16.4K |
| 2 |
SXL
Summit X LLC
Chesterfield,
Missouri
|
+$6.06K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.33K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$3.76K |
| 5 |
Strategic Wealth Investment Group
Louisville,
Kentucky
|
+$2.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Virtu Financial
New York
|
-$36K |
| 2 |
Jane Street
New York
|
-$31K |
| 3 |
Millennium Management
New York
|
-$14K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$12.7K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$9.48K |
SER Hedge Fund Activity: Q1 2022 in Review
32 of the 6,363 institutional investors tracked by Wall St. Rank reported a position in Serina Therapeutics (SER) for Q1 2022, worth a combined $4.09M — down 23% from $5.28M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SER and 2 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 5 added.
The largest buyer was Creative Planning, adding an estimated $16.4K. The largest seller was Virtu Financial, exiting entirely with an estimated $36K sold.
- 32 institutional investors held Serina Therapeutics (SER) as of Q1 2022, down from 35 in Q4 2021.
- Funds reported $4.09M of Serina Therapeutics stock for Q1 2022, down 23% quarter-over-quarter.
- 2 funds opened new Serina Therapeutics positions in Q1 2022 and 4 closed out, a net change of -2 holders.
- The largest Serina Therapeutics buyer in Q1 2022 was Creative Planning, an estimated $16.4K added.
- The largest Serina Therapeutics seller in Q1 2022 was Virtu Financial, an estimated $36K sold.
Based on aggregated 13F filings for Q1 2022.